71 – 80 of 135
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2009
-
Mark
Dose escalation of infliximab therapy in arthritis patients is related to diagnosis and concomitant methotrexate treatment: observational results from the South Swedish Arthritis Treatment Group register.
(
- Contribution to journal › Article
-
Mark
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial
(
- Contribution to journal › Article
-
Mark
Long-term follow-up of RA patients of the Hellenic Biologics Registry: comparison of first versus second anti-TNF-alpha therapy
(
- Contribution to journal › Published meeting abstract
-
Mark
Costs and outcomes for patients with rheumatoid arthritis treated with biological drugs in Sweden: a model based on registry data
(
- Contribution to journal › Article
-
Mark
Geriatric rheumatoid arthritis patients on delayed anti-TF-alpha agents have higher disease activity and experience more often serious adverse events compared to younger adults
(
- Contribution to journal › Published meeting abstract
-
Mark
Studies of mechanisms underlying the prolonged neutrophil survival in ANCA-associated systemic vasculitis
(
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register.
(
- Contribution to journal › Article
-
Mark
Efficacy and tolerability of anti-TNF therapy in psoriatic arthritis patients: Results from the South Swedish Arthritis Treatment Group Register.
(
- Contribution to journal › Article
-
Mark
The Swedish biologics register (ARTIS): observations of adverse events when using biologics in clinical practice
(
- Contribution to journal › Published meeting abstract
-
Mark
Why do women with early RA respond less well to MTX than men? Gender as a determinant of response in the initial phase of the Swefot trial
(
- Contribution to journal › Published meeting abstract